Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate

References

• Rinehart J F, Greenberg L D. Vitamin B6 deficiency in the rhesus monkey with particular reference to the occurrence of atherosclerosis, dental caries, and hepatic cirrhosis. Am J Clin Nutr 1956; 4: 318–28
   PubMedGoogle Scholar
• Mushett C W, Emerson G A. Arteriosclerosis in pyridoxine-deficient monkeys and dogs. Fed Proc 1956; 15: 526
   Google Scholar
• Kuzaya F. Experiment on arteriosclerosis and arteriolosclerosis induced in pyridoxine deficient monkeys and their recovery. J Primatol 1962; 3: 77
   Google Scholar
• Greenberg L D, Rinehart J F. Plasma cholesterol levels of cholesterol fed control and pyridoxine-deficient monkeys. Proc Soc Exper Biol Med 1951; 76: 580–3
   PubMedGoogle Scholar
• Vijayammal P L, Kurup P A. Pyridoxine and atherosclerosis: Role of pyridoxine in the metabolism of lipids and glycocaminoglycans in rats fed normal and high fat, high cholesterol diets containing 16% casein. Aust J Biol Sci 1978; 31: 7–20
   PubMedGoogle Scholar
• von Kleinsorge H, Zielke A. Untersuchung uber die Einwirkung verschiedener ungesättigter Fettsäuren und der Vitamine B6 and E auf die tierexperimentelle Arteriosklerose und das Verhalten der Serumlipoide beim Menschen. Therap Umsch 1959; 16: 367–80
   PubMedGoogle Scholar
• Yamada K, Fujii T, Motoyasu M. Influence of pyridoxal phosphate upon arteriosclerosis. Vitamins 1961; 22: 136–7
   Google Scholar
• Kuzuya F. Reversibility of atherosclerosis in pyridoxine-deficient monkeys. Atherosclerosis IV, Proceedings of the 4th international symposium. Springer-Verlag, Berlin 1977; 275–8
   Google Scholar
• Sheikh-Ali S D. The influence of vitamin B6 on the blood lipids and the cholesterolaemia under clinical and experimental conditions. Ter Arkh 1959; 9: 90–3
   Google Scholar
• Frolova I A, Oleneva V A, Sirota I I, Nikiforova G D. Effect of pyridoxine on patterns of lipid metabolism in patients with alimentary obesity. Vopr Med Khim 1975; 21: 299–306
   PubMedGoogle Scholar
• Stavenow L, Elmstahl S, Jerntorp P, Nilsson-Ehle P, Pessah-Rasmussen H, Galvard H, Hansen F, Samuelsson S-M. 80 year old men without cardiovascular disease in the community of Malmo. Part I. Social and medical factors with special reference to the lipoprotein pattern. J Internal Med 1990; 228: 9–15
   Google Scholar
• Pessah-Rasmussen H, Jerntorp P, Stavenow L, Elmstål S, Hansen F, Seidegård J, Galvard H, Brattström L, Hamfelt A. 80 year old men without cardiovascular disease in the community of Malmö. Part II. Smoking characteristics and ultrasound findings, with special reference to glutathione transferase and pyridoxal 5-phosphate. J Internal Med 1990; 228: 17–22
   Google Scholar
• Palareti G, Salardi S, Piazzi S, Legnani C, Poggi M, Grauso F, Caniato A, Coccheri S, Cacciari E. Blood coagulation changes in homocystinuria: effects of pyridoxone and other specific therapy. J Pediatr 1986; 109: 1001–6
   PubMedGoogle Scholar
• Danielsson B, Ekman R, Fex G, Johansson B-G, Kristensson H, Nilsson-Ehle P, Wadstein J. Changes in plasma high density lipoproteins in chronic male alcoholics during and after abuse. Scand J Clin Lab Invest 1978; 38: 113–9
   PubMed Web of Science ®Google Scholar
• Friedenwald W T, Levry R, Fredrickson D S. Estimation of the concentration of low density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMedGoogle Scholar
• Witten P W, Holman R T. Polyethenoid fatty acid metabolism. VI. Effect of pyridoxone on essential fatty acid conversion. Arch Biochem Biophys 1952; 41: 266–73
   PubMed Web of Science ®Google Scholar
• Wakil S J. Mechanism of fatty acid synthesis. J Lipid Res 1961; 2: 1–24
   Web of Science ®Google Scholar
• Havel R J. Lowering cholesterol, 1988, rationale, mechanisms, and means. J Clin Invest 1988; 81: 1653–60
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation: possible role in fibrin deposition in diabetes. Diabetes 1984; 33: 532–5
   PubMed Web of Science ®Google Scholar
• Shepard D C, Hitz J B, Dain J A. Pyridoxal 5-phosphate inhibits nonenzymatic glycosylation of proteins. Biochem Arch 1985; 1: 143–51
   Google Scholar
• Khatami M, Suldan Z, David I, Li W, Rockey J H. Inhibition effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci 1988; 43: 1725–31
   PubMed Web of Science ®Google Scholar
• Gonen B, Baenziger J, Schonfeld G, Jacobson D, Farrar P. Nonenzymatic glycosylation of low density lipoproteins in vitro. Effects on cell-interactive properties. Diabetes 1981; 30: 875–8
   PubMed Web of Science ®Google Scholar